Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism of action
Selegiline is a relatively selective inhibitor of monoamine oxidase type B that has been used in Parkinson’s disease as an adjunct to levodopa and as putative neuroprotective therapy. Clinical trials demonstrate that selegiline slows the rate of disease progression and delays the appearance of disability necessitating levodopa. However, confounding symptomatic effects have made it difficult to ascertain the presence of any direct neuroprotective effect. Laboratory studies demonstrate that selegiline protects dopaminergic neurons through a mechanism that does not involve MAO-B inhibition. Recent studies suggest that neuroprotection in laboratory models may be related to the capacity of selegiline to up-regulate a series of anti-oxidant and antiapoptotic molecules which promote cell survival. Further delineation of the precise mechanism whereby selegiline induces this effect may permit for the development of enhanced neuroprotective benefits in PD patients.
KeywordsPC12 Cell Monoamine Oxidase Parkinson Study Group UPDRS Score Monoamine Oxidase Type
Unable to display preview. Download preview PDF.
- 28.Yahr MD, Elizan TS, Moros D (1989) Selegiline in the treatment of Parkinson’s disease—long term experience. Acta Neurol Scand 128: 157–161Google Scholar
- 29.Olanow CW, Calne D (1991) Does selegiline monotherapy in Parkinson’s disease act by symptomatic or protective mechanisms? Neurology 42: 13–26Google Scholar
- 32.Hauser RA, Olanow CW, Koller WC (1994) Time course of wash-out of symptomatic medication in Parkinson’s disease. Neurology 44: 259Google Scholar
- 46.Tatton WG, Ju WYH, Wadia J, Tatton NA (1996) Reduction of neuronal apoptosis by small molecules: promise for new approaches to neurological therapy. In: Olanow CW, Jenner P, Youim MHB (eds) Neurodegeneration and prospects for neuroprotection in Parkinson’s disease. Academic Press, London, pp 202–220Google Scholar
- 47.Finnegan KT, Skratt JJ, Irwin I, et al (1990) Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. Eur J Pharmacol 184Google Scholar
- 53.Walkinshaw G, Waters CM (1995) Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA; implications for the treatment of Parkinson’s disease. J Clin Inv 2458–2464Google Scholar
- 60.Mytilineou C, Radcliffe P, Leonardi EK, et al (1996) L-Deprenyl protects mesencephalic dopamine neurons from glutamate-receptor-mediated toxicity. J Neurochem (in press)Google Scholar